logo

Aclaris Therapeutics (ACRS)



Trade ACRS now with
  Date
  Headline
9/5/2019 8:34:40 AM Aclaris Therapeutics Announces Completion Of Strategic Review Of Its Business
7/3/2019 4:06:22 PM Aclaris Therapeutics Appoints Maxine Gowen To Board Of Directors
6/17/2019 6:13:43 AM Aclaris Therapeutics Announces Positive 6-Month Results From A Phase 2 Open-Label Clinical Trial Of ATI-502
12/3/2018 7:19:03 AM Aclaris Therapeutics Closes Acquisition Of Worldwide Rights To RHOFADE Cream, 1%
10/22/2018 4:11:03 PM Aclaris Therapeutics Closes Public Offering Of 9.94 Mln Shares At $10.75/Shr
10/17/2018 9:54:19 PM Aclaris Therapeutics Prices Public Offering Of 8.65 Mln Shares At $10.75/shr
10/17/2018 4:01:57 PM Aclaris Therapeutics Intends To Offer And Sell Shares Of Its Common Stock
10/15/2018 4:01:36 PM Aclaris Therapeutics To Acquire Worldwide Rights To RHOFADE From Allergan
9/24/2018 7:07:02 AM Aclaris Therapeutics Announces First Patient Dosed In Phase 3 Studies Of A-101 45% In Patients With Common Warts
9/5/2018 4:02:04 PM Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/21/2018 7:04:37 AM Aclaris Therapeutics Announces ATI-450 Publication In The Journal Cancer Research
  
 
>